



Product Portfolio
Naturally Better.

Arthrex Aesthetics.



Welcome to Arthrex Aesthetics™

Naturally Better.

Arthrex is one of the world's leading companies in regenerative medicine, sports medicine, and minimally invasive (orthopedic) surgery. For four decades, Arthrex has been known for superior innovation and uncompromising quality. We have developed more than 18,000 products and surgical procedures, and we distribute medical devices in over 100 countries worldwide with the corporate mission of Helping Surgeons Treat Their Patients Better.

We are now proud to introduce Arthrex Aesthetics, bringing our decades of experience and globally renowned reputation to the world of aesthetic medicine. We are the global market leader for PRP/PRF systems and have been distributing our high-quality medical products for over 10 years in aesthetic medicine, dermatology, and plastic surgery. At Arthrex Aesthetics, we take pride in our dedication to making patients "Naturally Better."

Arthrex is also committed to medical education and research, and we train thousands of medical professionals worldwide each year in the safe and effective use of our products and procedures. Arthrex continues to experience unprecedented growth and demand for our products; however, we remain a privately held company with a family business culture committed to delivering uncompromising quality to the health care professionals who use our products, and ultimately, the millions of patients whose lives we impact.

05	Arthrex ACP® Double Syringe
09	ACP Max™ System
13	ACA Kit
17	Angel® PRP
23	FiberWire®
26	Ordering Information
28	References

Arthrex ACP[®] Double Syringe

Autologous Conditioned Plasma (ACP) | Fluid PRF

Trust the PRP/PRF industry's most researched product with 200+ scientific studies.



01

Fast and User Friendly

Using the Arthrex ACP double syringe, ACP can be prepared and applied within a few minutes. Intuitive processes with few handling steps help to avoid errors in its application.

02

Less Injection Pain

ACP does not contain anticoagulants, which can cause an unpleasant burning sensation when injected due to their pH levels. As a result, ACP can be injected into the patient with very little pain.

05

Efficient and Reproducible

15 mL of whole blood yield approximately 5-6 mL of ACP.

03

Safe to Handle


Certified as a medical device, the Arthrex ACP double syringe offers a closed, sterile, needle-free system for use in the practice or operating theater.

04


Made in Germany

The Arthrex ACP double syringe is manufactured in Germany. A quality management system in accordance with DIN ISO 13485 is in place to provide the highest safety standards.





2-3× platelets over baseline
in 5-6 mL ACP | fluid PRF



- › Closed, rapid, and simple production of ACP | fluid PRF
- › Completely autologous
- › No anticoagulants
- › No synthetic separation gels

Hematological Characteristics

The Arthrex ACP system enables the production of approx. 5-6 mL of ACP with a platelet concentration that is about 2-3 times increased over baseline, coupled with simultaneous depletion of leukocytes and erythrocytes.^{1,2}

The safety and clinical efficacy of ACP has been demonstrated in an FDA-approved level 1 study and over 200 other clinical trials.^{1,3-7}

ACP Max™ System

Highly Concentrated PRP Containing Platelet-Derived Exosomes

Discover our latest technology for higher platelet concentrations and safe delivery of autologous exosomes.



ACP Max™ System

Highly Concentrated PRP Containing Platelet-Derived Exosomes


The ACP Max system creates a highly concentrated platelet output from the patient's own blood, with up to 12 times platelet concentration over baseline, and significantly reduces neutrophils by up to 98.9%.⁸⁻¹⁰ Recent advances in the field have shown that highly concentrated autologous conditioned plasma formulations contain platelet-derived exosomes,¹¹ in addition to providing

increased concentrations of platelets and growth factors. Exosomes are small extracellular vesicles (EVs), ranging from 30 to 200 nanometers in size, that facilitate intercellular communication by transporting proteins, lipids, and nucleic acids between cells.¹² Exosomes have demonstrated potential therapeutic effects in anti-inflammatory and immunomodulatory applications,

tissue repair, and regeneration in preclinical and early clinical stages.^{13,14} These effects can be used in the treatment of wounds and scars in the skin, among other aesthetic applications.¹⁴⁻¹⁷ The ACP Max system enables an efficient concentration of platelets and offers a safe way to deliver autologous exosomes to support the patient's natural healing process.

Features and Benefits

- › Preparation of highly concentrated PRP containing platelet-derived exosomes at the point of care
- › Processing capabilities for volumes of 30 mL, 60 mL, or 90 mL
- › Increase of platelet concentration by up to 12× over baseline⁸⁻¹⁰
- › Effective reduction of neutrophils by up to 98.9% and erythrocytes by up to 99%⁸⁻¹⁰
- › Safe delivery of autologous platelet-derived exosomes
- › Sterile, triple-syringe system



First Spin


30 mL blood volume,
3200 rpm, 3 min

or

60 mL blood volume,
3200 rpm, 6 min

or

90 mL blood volume,
3200 rpm, 9 min



Second Spin


15 mL blood volume,
1500 rpm, 5 min



ACA Kit

Microfat for Volumization | SVF for Regeneration

Explore our techniques for lipofilling and the concentration of stromal vascular fraction (SVF) / adipose-derived stromal cells.



Arthrex Microfat | SVF

The ACA (autologous conditioned adipose tissue) technique offers an easy and fast solution for harvesting and processing non-homogenous liquids such as adipose tissue to generate microfat or SVF. Microfat is obtained after a single centrifugation, particle size is reduced to 1.2 mm, and adipocytes are kept intact for volumization. The SVF is isolated by mechanical dissociation of the adipocytes and a second centrifugation, whereby the stromal cells within the SVF can be collected as a pellet.¹⁸⁻²²

Major Effects of Microfat²³

- > Volumization
- > 3-dimensional effects


Major Effects of SVF²³

- > Tissue regeneration
- > Reduction of local inflammation
- > Reduction of tissue fibrosis




Surgical technique

Composition of Microfat



Composition of SVF



Adipocytes



Pericytes

- + CD140b⁺, CD146⁺, NG2⁺
- CD31⁻, CD34⁻, CD144⁻, vWF⁻



Pre-adipocytes



Adipose-derived stromal cells

- + CD13⁺, CD29⁺, CD34⁺/-, CD44⁺, CD90⁺, CD104a⁺,
- CD14⁻, CD31⁻, CD45⁻, CD106⁻, CD144⁻
- ? CD146⁻, αSMA⁻



Hematopoietic cells
Monocytes/macrophages



Extracellular matrix



Endothelial and progenitor cells

- + CD31⁺, CD34⁺, CD90⁺, CD146⁺, vWF⁺
- CD45⁻




Angel[®] PRP System

Fully Automated, Laser-Precise Cell Separation

Experience our most technically advanced system for the flexible and fully automated preparation of PRP.





Maximum Flexibility

One system for
all PRP applications

High Level of Security

Completely automated
separation in a closed
processing system

Ease of Use

PRP production at the
touch of a button


Maximum Flexibility and Ease of Use

Advantages of the Angel® System

Users can adjust platelet, leukocyte, and erythrocyte concentrations, and thus tailor the PRP therapy to the patient's needs. This is made possible by proprietary 3-sensor technology, which utilizes the absorption of different wavelengths of light by these cell types.

First, the whole blood is separated through a fully automated double centrifugation into 3 phases: erythrocytes; the buffy coat, which is rich in thrombocytes and leukocytes; and platelet-poor plasma (PPP). Then, the different phases pass through a sensor.


Thanks to the different light absorption behavior of the blood components, the sensor can not only distinguish between the individual phases, but also collect different partial fractions precisely and reproducibly. As the components of the buffy coat are distributed inhomogeneously at the transition to the erythrocyte-rich fraction, different PRP compositions can be obtained by changing the preset hematocrit value.




Adjustable platelet
(approximately 1-18 × above
baseline) and leukocyte/
neutrophil concentrations




Processing volume
per cycle:
40-180 mL






The Angel processing set
can be used up to 3 times in
succession for the same patient



A maximum of 540 mL of
patient blood can be pro-
cessed with 1 processing set



1. Platelet-poor plasma
2. Buffy coat
3. Erythrocytes

-  Lymphocytes and monocytes
-  Thrombocytes
-  Neutrophils, basophils, and eosinophils

Angel® System App

- > Available on any smart device
- > Based on over 8000 data points
- > Angelapp.arthrex.com

Individually Programmable

- > Preset reproducible, custom formulations
- > Storage of up to 30 user-specific processing logs



Angel PRP calculator



Hematocrit 2% 60 mL whole blood

- > 3 mL PRP volume
- > 4.6× platelet concentration in PRP over baseline
- > 0.3× neutrophil concentration in PRP over baseline



Hematocrit 7% 60 mL whole blood

- > 3 mL PRP volume
- > 6.8× platelet concentration in PRP over baseline
- > 1.2× neutrophil concentration in PRP over baseline

Closed and Secure


The Angel® Processing Set: Delivered Pre-assembled and Sterile

To protect patients from the risks of possible microbial contamination and to prevent the user from coming into contact with patient blood, the Angel processing set is delivered pre-assembled and sterile. The set can be positioned quickly and easily in just a few steps. After filling with patient blood, processing is fully automatic and closed. The individual fractions are collected in separate containers, which are fitted with Luer-activated valves (PPP and red blood cell (RBC) chamber) or can be used directly (PRP Luer syringe).

Process data can be saved for each processing. This data can then be easily transferred, as the Angel system has a USB port.



**Separate, sterile containers
for collecting PRP, PPP,
and RBC**




**USB connection
enables easy transfer
of process data**

FiberWire®

Anatomic Long-Lasting Fixation

Learn about our high-tech suture for minimal foreign-body reactions and anatomic long-lasting fixation.




FiberWire®

Strength and Performance You Can Count On!

FiberWire was the first high-strength suture on the market and continues to be preferred by surgeons around the world. The novel structure of FiberWire offers an ultra-high molecular weight polyethylene core that provides its superior strength and a coated, braided jacket that improves its tying characteristics and protects it from abrasion.

Arthrex and surgeons continue to develop new, innovative techniques with this product. FiberWire improves surgical outcomes by consistently providing optimal knot strength, loop security, abrasion resistance, and minimal elongation, which supports new procedures such as a minimally invasive brow lift with anatomic fixation.


Proven mechanical stability



Features and Benefits

Anatomic long-lasting fixation

Multi-filament core, braided jacket



Extremely robust
(ultra-high molecular weight polyethylene)

Easy to apply
(silicone elastomer coating, taper point needle)

Ordering Information

Arthrex ACP® Double Syringe

Arthrex ACP® double syringe, qty. 5	ABS-10014-E
Arthrex ACP® kit, series I	ABS-10011
HSW Soft-Ject®, 1 mL, LDS, Luer lock, qty. 100	8300018745

ACP Max™

ACP Max™	ABS-10013-E
ACP Max™ counterbalance	ABS-10017
HSW Soft-Ject®, 1 mL, LDS, Luer lock, qty. 100	8300018745

Anticoagulant

ACD-A, 20 mL, qty. 5	SAAV222.G00
----------------------	-------------

ACA Kit

ACA kit	ABS-10056
---------	-----------

Angel® System

Angel® system	ABS-10066
Angel® processing set, qty. 8	ABS-10064
Angel® PRP kit (incl. Angel® processing set)	ABS-10071
HSW Soft-Ject®, 1 mL, LDS, Luer lock, qty. 100	8300018745

FiberWire®

FiberWire® #3-0, braided polyblend suture, blue, with taper point needle, qty. 12	AR-7227-01
---	------------

Drucker Diagnostics Horizon Centrifuges

Drucker Diagnostics Horizon 24 AH centrifuge, 3 programs, with molded rotor	HORIZON 24-AH
Drucker Diagnostics Horizon 24 Flex AH	00389-129-000K
Spare bucket	03-1-0007-0123HK
Bucket spacer, for Arthrex ACP® double syringe	03-1-0001-0098K
Blood counterbalance, 15 mL, for centrifugation of Arthrex ACP® double syringe	03-1-0001-0070K
Fat counterbalance, 10 cc, for centrifugation of Arthrex ACP® double syringe	03-1-0001-0071K

Hettich Rotofix Centrifuges

Hettich Rotofix 32A, swing-out rotor, 220 V	1206-ART
Hettich Rotofix 32A, swing-out rotor, 110 V	1206-01-ART
Hettich ACP Max™ bucket	1490
Bucket spacer, for Arthrex ACP® double syringe	03-1-0001-0098K

References

1. Aust M, Pototschnig H, Jamchi S, Busch KH. Platelet-rich Plasma for Skin Rejuvenation and Treatment of Actinic Elastosis in the Lower Eyelid Area. *Cureus*. 2018;10(7):e2999. doi:10.7759/cureus.2999
2. Loibl M, Lang S, Brockhoff G, et al. The effect of leukocyte-reduced platelet-rich plasma on the proliferation of autologous adipose-tissue derived mesenchymal stem cells. *Clin Hemorheol Microcirc*. 2016;61(4):599-614. doi:10.3233/CH-141920
3. Smith PA. Intra-articular Autologous Conditioned Plasma Injections Provide Safe and Efficacious Treatment for Knee Osteoarthritis: An FDA-Sanctioned, Randomized, Double-blind, Placebo-controlled Clinical Trial. *Am J Sports Med*. 2016;44(4):884-891. doi:10.1177/0363546515624678
4. Hetz SP, Martin J, Pototschnig H. Patient Satisfaction and Clinical Effects of Platelet-Rich Plasma on Pattern Hair Loss in Male and Female Patients. *Cureus*. 2022;14(9):e28801. doi:10.7759/cureus.28801
5. Kloster BC, Paasch U. Illustrated Guide to Collagen Induction with Platelet-Rich Plasma (PRP). *Quintessence Publishing*; 2019
6. Eichler C, Najafpour M, Sauerwald A, Puppe J, Warm M. Platelet-rich plasma in the treatment of subcutaneous venous access device scars: a head-to-head patient survey. *Biomed Res Int*. 2015;2015:630601. doi:10.1155/2015/630601
7. Eichler C, Üner J, Thangarajah F, et al. Platelet-rich plasma (PRP) in oncological patients: long-term oncological outcome analysis of the treatment of subcutaneous venous access device scars in 89 breast cancer patients. *Arch Gynecol Obstet*. 2022;306(4):1171-1176. doi:10.1007/s00404-022-06416-4
8. Arthrex, Inc. Data on file (APT-05368). Naples, FL; 2021.
9. Arthrex, Inc. Data on file (APT-05535). Naples, FL; 2022.
10. Arthrex, Inc. Data on file (APT-05756). Naples, FL; 2022.
11. Torreggiani E, Perut F, Roncuzzi L, Zini N, Baglio SR, Baldini N. Exosomes: novel effectors of human platelet lysate activity. *Eur Cell Mater*. 2014;28:137-151. doi:10.22203/ecm.v028a11
12. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. *J Extracell Vesicles*. 2014;3:10.3402/jev.v3.24641. doi:10.3402/jev.v3.24641
13. Wu J, Piao Y, Liu Q, Yang X. Platelet-rich plasma-derived extracellular vesicles: A superior alternative in regenerative medicine?. *Cell Prolif*. 2021;54(12):e13123. doi:10.1111/cpr.13123
14. Gupta AK, Wang T, Rapaport JA, Talukder M. Therapeutic Potential of Extracellular Vesicles (Exosomes) Derived From Platelet-Rich Plasma: A Literature Review. *J Cosmet Dermatol*. 2025;24(2):e16709. doi:10.1111/jocd.16709
15. Guo SC, Tao SC, Yin WJ, Qi X, Yuan T, Zhang CQ. Exosomes derived from platelet-rich plasma promote the re-epithelization of chronic cutaneous wounds via activation of YAP in a diabetic rat model. *Theranostics*. 2017;7(1):81-96. doi:10.7150/thno.16803
16. Iyer SR, Scheiber AL, Yarowsky P, Henn RF 3rd, Otsuru S, Lovering RM. Exosomes Isolated From Platelet-Rich Plasma and Mesenchymal Stem Cells Promote Recovery of Function After Muscle Injury. *Am J Sports Med*. 2020;48(9):2277-2286. doi:10.1177/0363546520926462
17. Bai G, Truong TM, Pathak GN, Benoit L, Rao B. Clinical applications of exosomes in cosmetic dermatology. *Skin Health Dis*. 2024;4(6):e348. doi:10.1002/ski2.348
18. Stevens HP. ACA-Technik: „stromal vascular fraction“, „platelet-rich plasma“ und Mikrofett zur körpereigenen Regeneration und Hautverjüngung. *J Ästhet Chir*. 2018;12(2):77-83. doi:10.1007/s12631-018-0151-6
19. Prantl L, Brix E, Kempa S, et al. Facial Rejuvenation with Concentrated Lipograft-A 12 Month Follow-Up Study. *Cells*. 2021;10(3):594. doi:10.3390/cells10030594
20. Stevens HP, Donners S, de Bruijn J. Introducing Platelet-Rich Stroma: Platelet-Rich Plasma (PRP) and Stromal Vascular Fraction (SVF) Combined for the Treatment of Androgenetic Alopecia. *Aesthet Surg J*. 2018;38(8):811-822. doi:10.1093/asj/sjy029
21. Surowiecka A, Piekarski M, Pototschnig H. Stromal vascular fraction and emulsified fat as regenerative tools in rejuvenation of the lower eyelid area. *Dermatol Ther*. 2021;34(3):e14937. doi:10.1111/dth.14937
22. Klingenberg M, Dineva A, Hoyer A, et al. Injection of Autologous Adipose Stromal Vascular Fraction in Combination with Autologous Conditioned Plasma for the Treatment of Advanced Knee Osteoarthritis Significantly Improves Clinical Symptoms. *J Clin Med*. 2024;13(11):3031. doi:10.3390/jcm13113031
23. Surowiecka A, Strużyna J. Adipose-Derived Stem Cells for Facial Rejuvenation. *J Pers Med*. 2022;12(1):117. doi:10.3390/jpm12010117
24. Polykandriotis E, Ruppe F, Niederkorn M, et al. Polytetrafluoroethylene (PTFE) suture vs fiberwire and polypropylene in flexor tendon repair. *Arch Orthop Trauma Surg*. 2021;141(9):1609-1614. doi:10.1007/s00402-021-03899-9

Arthrex EMEA Headquarters

Arthrex GmbH | Erwin-Hielscher-Str. 9 | 81249 Munich | Germany

This description of technique is provided as an educational tool and clinical aid to assist properly licensed medical professionals in the usage of specific Arthrex products. As part of this professional usage, the medical professional must use their professional judgment in making any final determinations in product usage and technique. In doing so, the medical professional should rely on their own training and experience and should conduct a thorough review of pertinent medical literature and the product's Directions For Use.